In the phase 3 EMBER-3 trial, imlunestrant plus abemaciclib doubled median progression-free survival vs imlunestrant alone in ESR1-mutated advanced breast cancer.

Phase 3 trial shows trastuzumab botidotin boosts PFS and response rates vs T-DM1 in pretreated HER2-positive metastatic breast cancer, with manageable ocular toxicity.

During a live event, Ruta Rao, MD, and participants discussed how toxicity history, rather than head-to-head trial data, drives the choice among 3 antibody-drug conjugates once the first one fails or becomes intolerable.